|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005823,
umls-concept:C0022661,
umls-concept:C0030705,
umls-concept:C0059285,
umls-concept:C0205195,
umls-concept:C0332206,
umls-concept:C0392756,
umls-concept:C0442805,
umls-concept:C0597357,
umls-concept:C0680242,
umls-concept:C0857121,
umls-concept:C1527409,
umls-concept:C1707455
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2004-3-9
|
|
pubmed:abstractText |
Endothelin (ET) is implicated in the pathophysiology of chronic renal failure (CRF). We therefore studied the systemic and renal hemodynamic effects of ET receptor antagonists in CRF and examined differences between selective ETA, selective ETB, and combined ETA/B receptor blockade.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/BQ 788,
http://linkedlifedata.com/resource/pubmed/chemical/Endothelin-1,
http://linkedlifedata.com/resource/pubmed/chemical/Oligopeptides,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides, Cyclic,
http://linkedlifedata.com/resource/pubmed/chemical/Piperidines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Endothelin A,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Endothelin B,
http://linkedlifedata.com/resource/pubmed/chemical/Sodium,
http://linkedlifedata.com/resource/pubmed/chemical/cyclo(Trp-Asp-Pro-Val-Leu)
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1524-4539
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
9
|
|
pubmed:volume |
109
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1186-93
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14981006-Antihypertensive Agents,
pubmed-meshheading:14981006-Blood Pressure,
pubmed-meshheading:14981006-Cross-Over Studies,
pubmed-meshheading:14981006-Double-Blind Method,
pubmed-meshheading:14981006-Endothelin-1,
pubmed-meshheading:14981006-Hemodynamics,
pubmed-meshheading:14981006-Humans,
pubmed-meshheading:14981006-Hypertension, Renal,
pubmed-meshheading:14981006-Kidney,
pubmed-meshheading:14981006-Kidney Failure, Chronic,
pubmed-meshheading:14981006-Male,
pubmed-meshheading:14981006-Middle Aged,
pubmed-meshheading:14981006-Oligopeptides,
pubmed-meshheading:14981006-Peptides, Cyclic,
pubmed-meshheading:14981006-Piperidines,
pubmed-meshheading:14981006-Proteinuria,
pubmed-meshheading:14981006-Receptor, Endothelin A,
pubmed-meshheading:14981006-Receptor, Endothelin B,
pubmed-meshheading:14981006-Renal Circulation,
pubmed-meshheading:14981006-Sodium
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade.
|
|
pubmed:affiliation |
Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
